Machine learning for the prediction of survival post-allogeneic hematopoietic cell transplantation: A single-center experience
CONCLUSION: The application of multiple ML techniques on single center allogeneic HCT databases warrants further investigation and may provide a useful tool to identify variables with prognostic potential.PMID:37769635 | DOI:10.1159/000533665 (Source: Acta Haematologica)
Source: Acta Haematologica - September 28, 2023 Category: Hematology Authors: Hamed Shourabizadeh Dionne M Aleman Louis-Martin Rousseau Arjun D Law Auro Viswabandya Fotios V Michelis Source Type: research
Machine learning for the prediction of survival post-allogeneic hematopoietic cell transplantation: A single-center experience
CONCLUSION: The application of multiple ML techniques on single center allogeneic HCT databases warrants further investigation and may provide a useful tool to identify variables with prognostic potential.PMID:37769635 | DOI:10.1159/000533665 (Source: Acta Haematologica)
Source: Acta Haematologica - September 28, 2023 Category: Hematology Authors: Hamed Shourabizadeh Dionne M Aleman Louis-Martin Rousseau Arjun D Law Auro Viswabandya Fotios V Michelis Source Type: research
Intermittent high-dose glucocorticoid treatment does not cause adrenal insufficiency in patients with diffuse large B-cell lymphoma - a prospective study
In this study we investigated the incidence of GC-induced adrenal insufficiency in patients receiving intermittent short-term high-dose oral GC treatment for newly diagnosed diffuse large B-cell lymphoma. Cosyntropin stimulation test was used to assess adrenal function at study entry (baseline), at 2 months (before the 5th cycle), and 6 months from baseline (3 months after the last cycle). Ten patients were included (40% women). Mean age was 61 years. The mean (range) plasma morning cortisol was 407 (320-530) nmol/L at baseline, 373 (260-610) nmol/L at 2 months, and 372 (230-520) nmol/L 6 months from baseline. All patients...
Source: Acta Haematologica - September 27, 2023 Category: Hematology Authors: Margret Jona Einarsdottir Hallgerdur L Kristjansdottir Ragnhildur Bergthorsdottir Gudmundur Johannsson Penelope Trimpou Catharina Lewerin Oskar Ragnarsson Source Type: research
Intermittent high-dose glucocorticoid treatment does not cause adrenal insufficiency in patients with diffuse large B-cell lymphoma - a prospective study
In this study we investigated the incidence of GC-induced adrenal insufficiency in patients receiving intermittent short-term high-dose oral GC treatment for newly diagnosed diffuse large B-cell lymphoma. Cosyntropin stimulation test was used to assess adrenal function at study entry (baseline), at 2 months (before the 5th cycle), and 6 months from baseline (3 months after the last cycle). Ten patients were included (40% women). Mean age was 61 years. The mean (range) plasma morning cortisol was 407 (320-530) nmol/L at baseline, 373 (260-610) nmol/L at 2 months, and 372 (230-520) nmol/L 6 months from baseline. All patients...
Source: Acta Haematologica - September 27, 2023 Category: Hematology Authors: Margret Jona Einarsdottir Hallgerdur L Kristjansdottir Ragnhildur Bergthorsdottir Gudmundur Johannsson Penelope Trimpou Catharina Lewerin Oskar Ragnarsson Source Type: research
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022
CONCLUSION: A majority of AML clinical trials, particularly in the non-transplant setting, exclude patients with CNS involvement. Many of these trials, most notably phase 3 trials, exclude patients not only with active, but any history of CNS involvement. Further research is needed to determine optimal management of these patients in order to increase representation in large clinical trials.PMID:37751713 | DOI:10.1159/000533819 (Source: Acta Haematologica)
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Dahniel Sastow Grace Van Hyfte Jonathan Feld Marina Kremyanskaya John Mascarenhas Douglas Tremblay Source Type: research
Limited efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse
Acta Haematol. 2023 Sep 26. doi: 10.1159/000534026. Online ahead of print.ABSTRACTThe recently approved Bcl-2 inhibitor venetoclax (VEN) has achieved promising outcomes in new and relapsed/refractory (R/R) acute myeloid leukemia (AML). Although its use is not well-established in R/R AML with extramedullary disease (EMD), some reports have shown promising outcomes. We retrospectively analyzed 11 patients of R/R AML with EMD [with (n=4) or without (n=7) concurrent marrow involvement], who were treated with VEN plus decitabine (n=9) or low-dose cytarabine (n=2) between May 2020 and October 2020 in Seoul St. Mary's Hospital. T...
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Soyoung Bae Seungwon Sa Silvia Park Byung-Sik Cho Hee-Je Kim Source Type: research
Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region
CONCLUSION: In recent years, CLL management has progressed significantly with many diagnostic tests and several novel treatments becoming available. This consensus gathers decades of consolidated principles, novel research, and promising prospects for the management of this disease.PMID:37751733 | DOI:10.1159/000531675 (Source: Acta Haematologica)
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Salem H Alshemmari Mustaqeem A Siddiqui Ramesh Pandita Hani Y Osman Honar Cherif Susan O'Brien Mahmoud Marashi Khalil Al Farsi Source Type: research
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022
CONCLUSION: A majority of AML clinical trials, particularly in the non-transplant setting, exclude patients with CNS involvement. Many of these trials, most notably phase 3 trials, exclude patients not only with active, but any history of CNS involvement. Further research is needed to determine optimal management of these patients in order to increase representation in large clinical trials.PMID:37751713 | DOI:10.1159/000533819 (Source: Acta Haematologica)
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Dahniel Sastow Grace Van Hyfte Jonathan Feld Marina Kremyanskaya John Mascarenhas Douglas Tremblay Source Type: research
Limited efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse
Acta Haematol. 2023 Sep 26. doi: 10.1159/000534026. Online ahead of print.ABSTRACTThe recently approved Bcl-2 inhibitor venetoclax (VEN) has achieved promising outcomes in new and relapsed/refractory (R/R) acute myeloid leukemia (AML). Although its use is not well-established in R/R AML with extramedullary disease (EMD), some reports have shown promising outcomes. We retrospectively analyzed 11 patients of R/R AML with EMD [with (n=4) or without (n=7) concurrent marrow involvement], who were treated with VEN plus decitabine (n=9) or low-dose cytarabine (n=2) between May 2020 and October 2020 in Seoul St. Mary's Hospital. T...
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Soyoung Bae Seungwon Sa Silvia Park Byung-Sik Cho Hee-Je Kim Source Type: research
Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region
CONCLUSION: In recent years, CLL management has progressed significantly with many diagnostic tests and several novel treatments becoming available. This consensus gathers decades of consolidated principles, novel research, and promising prospects for the management of this disease.PMID:37751733 | DOI:10.1159/000531675 (Source: Acta Haematologica)
Source: Acta Haematologica - September 26, 2023 Category: Hematology Authors: Salem H Alshemmari Mustaqeem A Siddiqui Ramesh Pandita Hani Y Osman Honar Cherif Susan O'Brien Mahmoud Marashi Khalil Al Farsi Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
Chronic lymphocytic leukemia: disease biology
Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610. Online ahead of print.ABSTRACTB cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inh...
Source: Acta Haematologica - September 17, 2023 Category: Hematology Authors: Stefan Koehrer Jan A Burger Source Type: research
